康弘药业 (002773.SZ) Latest Company News

Sep 3, 2026, 09:44 UTC
Kanghong Pharmaceutical's wholly-owned subsidiary Chengdu Kanghong Biologics received regulatory approval from China's National Medical Products Administration to add a new indication for its Conbercept ophthalmic injection (brand name Lumitin), specifically for treating retinopathy of prematurity, marking the fifth approved indication for the drug.
Source:
- finance.sina.cn
Aug 25, 2026, 10:07 UTC
Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.
Source:
- finance.sina.cn
Aug 19, 2026, 12:45 UTC
Kanghong Pharmaceutical's subsidiary Kanghong Biologics received a drug registration certificate from Guyana's FDA for Langmu (Conbercept ophthalmic injection), granting market access in Guyana for treating wet age-related macular degeneration.
Source:
- finance.sina.cn
Aug 6, 2026, 10:53 UTC
Kanghong Pharmaceutical used 50 million yuan of its own funds to purchase a principal-guaranteed floating-income structured deposit product issued by Bank of Chengdu, with a term of 92 days, value date August 6, 2026, and maturity date November 6, 2026.
Source:
- finance.sina.cn
Aug 2, 2026, 08:13 UTC
Kanghong Pharmaceutical announced on 2026-07-31 that its Perampanel tablets were provisionally selected in the 12th batch of national centralized drug procurement, specification 2mg, 28 tablets per box, for epilepsy treatment, with procurement cycle until 2029-12-31.
Source:
- finance.sina.cn

002773.SZ

Kanghong Pharmaceutical announced its 2026 first-half results: net profit attributable to shareholders was 565 million yuan, down 22.61% year-on-year.

Kanghong Pharmaceutical's subsidiary Kanghong Biologics received a drug registration certificate from Guyana's FDA for Langmu (Conbercept ophthalmic injection), granting market access in Guyana for treating wet age-related macular degeneration.

Kanghong Pharmaceutical used 50 million yuan of its own funds to purchase a principal-guaranteed floating-income structured deposit product issued by Bank of Chengdu, with a term of 92 days, value date August 6, 2026, and maturity date November 6, 2026.

Kanghong Pharmaceutical announced on 2026-07-31 that its Perampanel tablets were provisionally selected in the 12th batch of national centralized drug procurement, specification 2mg, 28 tablets per box, for epilepsy treatment, with procurement cycle until 2029-12-31.